Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Autolus Therapeutics to post earnings of ($0.21) per share and revenue of $2.98 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Autolus Therapeutics Stock Performance
AUTL stock opened at $1.79 on Wednesday. The firm has a market cap of $476.31 million, a price-to-earnings ratio of -1.48 and a beta of 2.07. The firm has a 50-day simple moving average of $2.06 and a two-hundred day simple moving average of $2.95. Autolus Therapeutics has a one year low of $1.68 and a one year high of $6.63.
Analyst Ratings Changes
Separately, Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.40.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
- Five stocks we like better than Autolus Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3 Must-Own Stocks to Build Wealth This Decade
- Where Do I Find 52-Week Highs and Lows?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.